Clinical Trials Browser

Phase 2 × Completed × olaparib × Clear all

NCT05005728 2026-05-05

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Completed

Prostatic Neoplasms

NCT05156268 2026-04-27

A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Phase 2 Completed

GynecologicSarcoma

Endometrial Carcinosarcoma

NCT03462342 2026-04-13

CAPRI

Phase 2 Completed

High Grade Serous Carcinoma

NCT05340413 2026-03-16

RADIOLA

Phase 2 Completed

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04191135 2026-03-03

KEYLYNK-009

Phase 2 Completed

462 enrolled 30 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Triple Negative Breast Neoplasms

NCT03025035 2026-02-06

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer

Phase 2 Completed

14 enrolled 8 charts

Breast Neoplasms

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Neoplasms, Unknown Primary

NCT03516812 2025-09-29

Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer

Phase 2 Completed

36 enrolled 14 charts

Castration-Resistant Prostate Carcinoma

NCT03561870 2025-09-12

OLAGLI

Phase 2 Completed

Glioma, Recurrence

NCT04076579 2025-08-29

Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Phase 2 Completed

29 enrolled 13 charts

Sarcoma

NCT01078662 2025-08-13

Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats

Phase 2 Completed

298 enrolled 18 charts

BreastGastrointestinalGenitourinaryGynecologic

Ovarian

NCT04306367 2025-02-17

Study of Pembrolizumab and Olaparib in Bile Duct Cancer

Phase 2 Completed

14 enrolled 13 charts

Gastrointestinal

Cholangiocarcinoma

NCT00753545 2025-02-03

Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer

Phase 2 Completed

265 enrolled 25 charts 1 FDA

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02533765 2025-01-30

Olaparib as Salvage Treatment for Cisplatin-resistant Germ Cell Tumor

Phase 2 Completed

Neoplasms, Germ Cell and Embryonal

NCT03314740 2025-01-10

BAROCCO

Phase 2 Completed

123 enrolled 14 charts

Ovarian Neoplasms

NCT03233204 2024-12-11

Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)

Phase 2 Completed

6 enrolled 12 charts

CNSGastrointestinalGenitourinaryLymphoidMyeloidSarcoma

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

NCT03745950 2024-12-04

UTOLA

Phase 2 Completed

Endometrial Neoplasms

NCT03838744 2024-12-04

TOMAS2

Phase 2 Completed

Sarcoma

NCT02953457 2024-11-19

Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation

Phase 2 Completed

40 enrolled 16 charts

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03205761 2024-10-18

COMETABreast

Phase 2 Completed

11 enrolled 20 charts

Advanced Breast Cancer

NCT02677038 2024-10-01

Olaparib in Treating Patients With Stage IV Pancreatic Cancer

Phase 2 Completed

24 enrolled 8 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02937818 2024-06-07

A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer

Phase 2 Completed

72 enrolled 29 charts

Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma

NCT03127215 2024-05-08

NCT-PMO-1603

Phase 2 Completed

Cancers With DNA Repair-Deficiency

NCT03117933 2024-01-23

OCTOVA

Phase 2 Completed

Ovarian Neoplasms

NCT00494234 2024-01-19

ICEBERG 1

Phase 2 Completed

54 enrolled 17 charts

BreastClassical hematology

Fanconi Anemia, Complementation Group D1, Breast Neoplasms

NCT02117167 2024-01-10

SAFIR02_Lung

Phase 2 Completed

Non-small Cell Lung Cancer Metastatic

NCT03448718 2023-11-22

Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Phase 2 Completed

19 enrolled 9 charts

Metastatic Urothelial Cancer

NCT01972217 2023-11-14

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Phase 2 Completed

158 enrolled 32 charts

Prostatic Neoplasms

NCT04166435 2023-09-06

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Phase 2 Completed

11 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT04669002 2023-08-02

EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

Phase 2 Completed

Ovarian Neoplasms

NCT01063517 2023-07-20

Efficacy Study of Olaparib With Paclitaxel Versus Paclitaxel in Gastric Cancer Patients

Phase 2 Completed

124 enrolled 27 charts

Gastrointestinal

Stomach Neoplasms

NCT00679783 2023-07-12

Phase II Study of AZD2281 in Patients With Known BRCA Mutation Status or Recurrent High Grade Ovarian Cancer or Patients With Known BRCA Mutation Status/ Triple Neg Breast Cancer

Phase 2 Completed

99 enrolled 17 charts

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT04417192 2023-07-06

OLAPem

Phase 2 Completed

Ovarian Neoplasms

NCT02511223 2023-04-19

10

Phase 2 Completed

Gastrointestinal

Pancreatic Neoplasms

NCT03161132 2023-01-27

ROLANDO

Phase 2 Completed

Advanced Ovarian Cancer

NCT03434158 2022-11-03

IMANOL

Phase 2 Completed

Prostate Cancer Metastatic

NCT03470805 2022-09-23

Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

Phase 2 Completed

Ovarian Neoplasms

NCT02983799 2022-04-13

Olaparib Tablets as a Treatment for Ovarian Cancer Subjects With Different HRD Tumor Status

Phase 2 Completed

272 enrolled 14 charts

Ovarian Neoplasms

NCT02889900 2022-03-08

CONCERTO

Phase 2 Completed

62 enrolled 15 charts

Ovarian Neoplasms

NCT03531840 2021-04-09

Olaparib in People With Malignant Mesothelioma

Phase 2 Completed

23 enrolled 16 charts

Other solid neoplasmThoracic

Mesothelioma

NCT03009682 2021-02-18

SUKSES-B

Phase 2 Completed

Small Cell Lung Carcinoma

NCT03428607 2021-02-18

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

Phase 2 Completed

SCLC

NCT03534492 2020-04-06

NEODURVARIB

Phase 2 Completed

Urinary Bladder Neoplasms

NCT02882308 2020-02-07

OPHELIA

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT00628251 2019-12-05

ICEBERG 3

Phase 2 Completed

97 enrolled 22 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT00494442 2018-08-01

ICEBERG 2

Phase 2 Completed

58 enrolled 13 charts

Classical hematologyGynecologic

Fanconi Anemia, Complementation Group D1, Ovarian Neoplasms

NCT02340611 2018-06-12

A Study of Cediranib and Olaparib at the Time Ovarian Cancer Worsens on Olaparib

Phase 2 Completed

Ovarian Neoplasms

NCT01583543 2017-05-19

Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma

Phase 2 Completed

12 enrolled 7 charts

Neoplasm Metastasis, Recurrence, Sarcoma, Ewing

NCT00912743 2016-11-09

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Phase 2 Completed

33 enrolled 9 charts

Gastrointestinal

Colorectal Neoplasms